A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

ClinicalTrials.gov ID: NCT07840326

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07840326. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.

Study identification

NCT ID: NCT07840326
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Sundance Biosciences, Inc.; Industry
Enrollment: 20 participants

Conditions and interventions

Conditions

Interventions

SUN-627 Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2026 (Estimated)
Primary completion: Jun 2027 (Estimated)
Completion: Jul 2027 (Estimated)
Last update posted: Oct 30, 2026

2026 – 2027

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
Local Institution - Site 103	Tampa	Florida	33612	Recruiting
Local Institution - Site 102	Atlanta	Georgia	30309	Recruiting
Local Institution - Site 106	Stony Brook	New York	11794	Not yet recruiting
Local Institution - Site 101	Raleigh	North Carolina	27607	Recruiting
Local Institution - Site 104	Columbus	Ohio	43235	Recruiting
Local Institution - Site 105	Oklahoma City	Oklahoma	73104	Recruiting
Local Institution - Site 107	Dallas	Texas	75390	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07840326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 30, 2026 · Synced Nov 14, 2026